{
    "xml": "<topic id=\"PHP8407\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/tick-borne-encephalitis-vaccine-inactivated\" basename=\"tick-borne-encephalitis-vaccine-inactivated\" title=\"TICK-BORNE ENCEPHALITIS VACCINE, INACTIVATED\">\n<title>TICK-BORNE ENCEPHALITIS VACCINE, INACTIVATED</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1330\" namespace=\"/interactions/list-of-drug-interactions/vaccines/tick-borne-encephalitis-vaccine\">Tick-borne Encephalitis Vaccine</xref>\n</p>\n<data name=\"vtmid\">333699008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_581448509\" title=\"Vaccines\">Vaccines</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34568\" title=\"VACCINES\" namespace=\"/drug-classes/vaccines\">VACCINES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP36414\" outputclass=\"indicationsAndDose\" rev=\"1.40\" parent=\"/drugs/tick-borne-encephalitis-vaccine-inactivated\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Initial immunisation against tick-borne encephalitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;15 years</p>\n<p>0.25&#8239;mL for 1 dose, followed by 0.25&#8239;mL after 1&#8211;3&#8239;months for 1 dose, then 0.25&#8239;mL after 5&#8211;12&#8239;months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region or anterolateral thigh in infants, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8211;3&#8239;months for 1 dose, then 0.5&#8239;mL after 5&#8211;12&#8239;months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8211;3&#8239;months for 1 dose, then 0.5&#8239;mL after 5&#8211;12&#8239;months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8211;3&#8239;months for 1 dose, then 0.5&#8239;mL after 5&#8211;12&#8239;months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against tick-borne encephalitis, booster doses</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;17 years</p>\n<p>First dose to be given within 3 years after initial course completed and then every 3&#8211;5 years (consult product literature).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>First dose to be given within 3 years after initial course completed and then every 3&#8211;5 years (consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP36598\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.14\" parent=\"/drugs/tick-borne-encephalitis-vaccine-inactivated\">\n<title>Allergy and cross-sensitivity</title>\n<body>\n<section outputclass=\"allergyAndCrossSensitivityContraindications\">\n<sectiondiv>\n<p>Individuals with evidence of previous anaphylactic reaction to egg should not be given tick-borne encephalitis vaccine.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP8407-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tick-borne-encephalitis-vaccine-inactivated\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74670\" title=\"Suspension for injection\" namespace=\"/drugs/tick-borne-encephalitis-vaccine-inactivated/suspension-for-injection\">Suspension for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78335\" namespace=\"/treatment-summaries/vaccines\" title=\"Vaccines\" count=\"1\" rel=\"backlink\">Vaccines</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1330\" namespace=\"/interactions/list-of-drug-interactions/vaccines/tick-borne-encephalitis-vaccine\" title=\"Tick-borne Encephalitis Vaccine\" count=\"1\" rel=\"link\">Tick-borne Encephalitis Vaccine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34568\" namespace=\"/drug-classes/vaccines\" title=\"VACCINES\" count=\"1\" rel=\"link\">VACCINES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74670\" namespace=\"/drugs/tick-borne-encephalitis-vaccine-inactivated/suspension-for-injection\" title=\"Suspension for injection\" count=\"1\" rel=\"link\">Suspension for injection</xref>\n</links>\n</topic>",
    "id": "PHP8407",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/tick-borne-encephalitis-vaccine-inactivated",
    "basename": "tick-borne-encephalitis-vaccine-inactivated",
    "title": "TICK-BORNE ENCEPHALITIS VACCINE, INACTIVATED",
    "interactants": [
        {
            "id": "bnf_int_1330",
            "label": "Tick-borne Encephalitis Vaccine"
        }
    ],
    "vtmid": "333699008",
    "drugClassification": [
        "Vaccines"
    ],
    "inheritsFromClass": [
        "VACCINES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Initial immunisation against tick-borne encephalitis",
                        "html": "Initial immunisation against tick-borne encephalitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "0.25 mL for 1 dose, followed by 0.25 mL after 1&#8211;3 months for 1 dose, then 0.25 mL after 5&#8211;12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region or anterolateral thigh in infants, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.",
                        "html": "<p>0.25&#8239;mL for 1 dose, followed by 0.25&#8239;mL after 1&#8211;3&#8239;months for 1 dose, then 0.25&#8239;mL after 5&#8211;12&#8239;months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region or anterolateral thigh in infants, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.</p>",
                        "ageGroup": "1&#8211;15 years"
                    },
                    {
                        "textContent": "0.5 mL for 1 dose, followed by 0.5 mL after 1&#8211;3 months for 1 dose, then 0.5 mL after 5&#8211;12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.",
                        "html": "<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8211;3&#8239;months for 1 dose, then 0.5&#8239;mL after 5&#8211;12&#8239;months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "0.5 mL for 1 dose, followed by 0.5 mL after 1&#8211;3 months for 1 dose, then 0.5 mL after 5&#8211;12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.",
                        "html": "<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8211;3&#8239;months for 1 dose, then 0.5&#8239;mL after 5&#8211;12&#8239;months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.</p>"
                    },
                    {
                        "textContent": "0.5 mL for 1 dose, followed by 0.5 mL after 1&#8211;3 months for 1 dose, then 0.5 mL after 5&#8211;12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.",
                        "html": "<p>0.5&#8239;mL for 1 dose, followed by 0.5&#8239;mL after 1&#8211;3&#8239;months for 1 dose, then 0.5&#8239;mL after 5&#8211;12&#8239;months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against tick-borne encephalitis, booster doses",
                        "html": "Immunisation against tick-borne encephalitis, booster doses"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "First dose to be given within 3 years after initial course completed and then every 3&#8211;5 years (consult product literature).",
                        "html": "<p>First dose to be given within 3 years after initial course completed and then every 3&#8211;5 years (consult product literature).</p>",
                        "ageGroup": "1&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "First dose to be given within 3 years after initial course completed and then every 3&#8211;5 years (consult product literature).",
                        "html": "<p>First dose to be given within 3 years after initial course completed and then every 3&#8211;5 years (consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "allergyAndCrossSensitivity": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Individuals with evidence of previous anaphylactic reaction to egg should not be given tick-borne encephalitis vaccine.",
                "html": "<p>Individuals with evidence of previous anaphylactic reaction to egg should not be given tick-borne encephalitis vaccine.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74670",
                "label": "Suspension for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78335",
                "label": "Vaccines",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1330",
                "label": "Tick-borne Encephalitis Vaccine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34568",
                "label": "VACCINES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74670",
                "label": "Suspension for injection",
                "type": "medicinalForm"
            }
        ]
    }
}